Recently, Sinopharm Accord (Jiuzhou Tong) announced that an injectable solution developed by its subsidiary has received marketing approval from China’s National Medical Products Administration (NMPA). The injection is indicated for specific conditions such as infectious diseases or complications associated with chronic illnesses, marking a significant step forward for the company in the fields of advanced drug formulations and innovative pharmaceuticals. As a leading pharmaceutical distribution and supply chain service provider in China, Jiuzhou Tong has been actively expanding upstream along the pharmaceutical value chain in recent years, leveraging its subsidiaries to strengthen capabilities in drug R&D and manufacturing. This newly approved injectable not only diversifies the company’s product portfolio but also enhances its competitiveness in the specialty drug market. Industry analysts note that the product’s launch is expected to generate new revenue streams and reinforce Jiuzhou Tong’s strategic position in integrated pharmaceutical industrial and commercial operations. Moving forward, the company plans to increase investment in R&D to bring more high-quality medicines to clinical use, contributing to the high-quality development of China’s pharmaceutical industry.
近日，九州通医药集团宣布其子公司生产的某注射液已获得国家药品监督管理局（NMPA）批准上市。该注射液主要用于治疗特定适应症，如感染性疾病或慢性病相关并发症，标志着九州通在高端制剂和创新药领域迈出重要一步。作为中国领先的医药流通与供应链服务企业，九州通近年来积极向产业链上游延伸，通过旗下子公司布局药品研发与生产，提升自主创新能力。此次获批的注射液不仅丰富了公司产品线，也增强了其在专科用药市场的竞争力。业内分析指出，该产品的上市有望为公司带来新的营收增长点，并进一步巩固其在医药工业与商业一体化发展中的战略地位。未来，九州通将继续加大研发投入，推动更多高质量药品进入临床应用，助力中国医药产业高质量发展。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/9523.html